Dechra inks exclusive licensing deal with Kane Biotech

1 min

Venable represented Dechra Veterinary Products LLC ("Dechra"), a leading veterinary pharmaceutical company dedicated to the animal healthcare market, in an exclusive licensing deal with Kane Biotech, Inc. ("Kane"), a biotechnology company engaged in the development of technologies that prevent and remove microbial biofilms. Under the terms of the deal, Kane grants Dechra an exclusive license to market, commercialize and distribute certain oral care and dermatology products in the North American veterinary market. Dechra secured the same exclusive rights with respect to certain products developed in the future that utilize Kane's patented and patent-pending biofilm technology. The deal is viewed as a significant opportunity for Dechra to build market share in strategic segments of the veterinarian market. The Venable team consisted of Jim Nelson and Cameron Cole, with assistance from Friedemann Thomma on international tax issues.